Here’s some hopeful news for women weighing their options on GLP-1 weight-loss medications: a major analysis suggests these drugs may do more than help with pounds on the scale — they could also be linked to lower risk of certain cancers.
The study, published in JAMA Oncology and covered by Fox News, looked at health records from 2014–2024 for 86,632 adults with obesity who were eligible for anti-obesity meds (about two-thirds were women).
Researchers found a significantly lower overall cancer risk among GLP-1 users, with the biggest reductions seen in women’s cancers like endometrial and ovarian, as well as meningioma, compared with non-users. One important caveat: there was an association with a higher risk of kidney cancer, underscoring the need for ongoing monitoring and more research.
What makes this especially noteworthy for women over 35 is the potential for prevention in cancers often tied to obesity and hormonal factors. As gynecologic oncologist Dr. Brian Slomovitz told Fox News, the link between GLP-1s and reduced risk in obesity-driven cancers is “not surprising.” He adds,
“The opportunities [for GLP-1s] are tremendous, and if the studies are positive, that’s game-changing.” For many women, especially after childbearing years or following cancer treatment, the idea that a weight-loss medication might also support cancer risk reduction and overall metabolic health is a compelling dual benefit.
Mechanistically, experts point out that losing weight can reduce fat-derived estrogen and systemic inflammation — both contributors to certain cancers. Patients in practice also report feeling lighter, more energized, and more motivated to exercise and maintain healthy habits.
Still, GLP-1s aren’t for everyone: side effects like nausea or pancreatitis are real, and the kidney cancer signal needs clarity in longer-term follow-up. It’s wise to work closely with a knowledgeable clinician to weigh personal risks and benefits.
GLP-1s are reshaping the conversation from “weight loss only” to potential disease prevention and quality-of-life gains — especially in conditions that disproportionately affect women. If future studies confirm these protective effects, GLP-1s could become a pillar not just of weight management but of women’s health strategy across midlife and beyond.
Curious to learn more and see the full context? Read the Fox News report here: https://www.foxnews.com/health/weight-loss-drugs-now-linked-cancer-protection-women-major-new-study-reveals
